Treatment of Relapsed/Refractory Myeloma (excluding T-cell redirection therapy)
Indirect comparison of linvoseltamab versus talquetamab for triple-class exposed (TCE) relapsed/refractory multiple myeloma (RRMM)
Joshua Richter, MD
Associate Professor of Medicine
Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA
New York, New York, United States